The bull case for Nebius: 571% revenue growth and 4x FY 2027 revenue guidance make its 2.8x forward sales multiple look ...

The following slide deck was published by Altimmune, Inc. in conjunction with this event.

Analyst rates Rocket Lab a Strong Buy with a $100 target: backlog rose 52% sequentially to $3.57 billion, while Neutron ...

I remain bullish on Enbridge (ENB): at 11.4 times DCF and a 5.68% forward yield, shares could retake the low $50s within 12 ...

The bull case for QQQI: volatility supports monthly income, and its $7.63 trailing distribution implies a 14.96% yield; the ...

Mineral royalty companies offer a capital-light way to capture cash flows tied to energy production and commodity prices.

The bull case for a modified Harry Browne's Permanent Portfolio: real assets, gold and dividend stocks target 7%-8% yields ...

A quick note before we start: on Saturdays, I share what Main Street Alpha members received during the week. And with our ...

AVITA Medical is rated Buy with a $20 twelve-month target, driven by a Medicare reimbursement reset effective January 1. RCEL ...

Sean Duffy says a L3Harris-managed system upgrade preceded Friday’s ground stop; investigators are checking for installation ...

Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a pivotal FDA decision on ...

Analyst rates VICI Properties a Buy at a 7%+ yield and 10x AFFO; a $30.60 base case implies 23% upside if Caesars and MGM ...